Bredin Prat advises JJDC in connection with its equity investment and worldwide licence agreement with Nanobiotix for the co-development and commercialisation of investigational radiotherapy enhancer “NBTXR3”

Bredin Prat is advising Johnson & Johnson Innovation – JJDC (“JJDC”), the strategic venture capital arm of the Johnson & Johnson Family of Companies, the US pharmaceuticals giant, in connection with its equity investment and worldwide licence agreement with Nanobiotix for the co-development and commercialisation of its new product candidate “NBTXR3”, trial name “NANORAY-312”, which increases the efficacy of radiotherapy for the treatment of cancer.

Nanobiotix is a French late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer. The company has been listed in Paris since 2012 and in New York since 2020.

Under the terms of this licence agreement, Nanobiotex will grant JJDC a worldwide licence which is to be exclusive, except territories already licensed by Nanobiotex to its Chinese partner LianBio.

Nanobiotix will receive near term cash and operational support valued up to US$60 million. This includes an upfront cash licensing fee of US$30 million, and in-kind regulatory and development support for study NANORAY-312 valued at up to US$30 million, that JJDC may provide at its sole discretion.

Nanobiotix is eligible to receive up to US$30 million in equity investments from JJDC through share capital increases with cancellation of existing shareholders’ preferential subscription rights in two successive tranches.

The licence agreement will become effective once the customary closing conditions have been met, including clearance by US antitrust authorities under the Hart-Scott-Rodino Act.

The Bredin Prat team advising Johnson & Johnson Innovation – JJDC comprised Corporate lawyers Olivier Saba and Kate Romain (partners), Douceline Chabord and Fawzi Khattabi.